NASDAQ · PODD
Insulet Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PODD: Nov 04, 2026
Insulet Corporation Common Stock is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $1.59. The reported EPS for the same quarter last year was $1.24.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.59 | $1.66 | $1.50 | 8 |
| Dec 2026 | $1.84 | $1.88 | $1.77 | 7 |
| Mar 2027 | $1.62 | $1.69 | $1.53 | 5 |
| Jun 2027 | $1.83 | $1.90 | $1.76 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest · Fintel · MarketBeat- Zacks · Oct 28, 9:00 AM EDTInsulet (PODD) Reports Next Week: Wall Street Expects Earnings GrowthInsulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- BNK Invest · Oct 21, 4:46 PM EDTAlign Technology Takes Over #479 Spot From InsuletIn the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Align Technology Inc (Symbol: ALGN) has taken over the #479 spot from Insulet Corp (Symbol: PODD), according to The Online Investor. Market capitalization is an impor
- Zacks · Oct 20, 9:50 AM EDTDexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT StudyDXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.
- Zacks · Oct 16, 8:45 AM EDTHere's Why Insulet (PODD) is a Strong Growth StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- Fintel · Oct 7, 5:40 PM EDTBarclays Initiates Coverage of Insulet with Equal-Weight RatingFintel reports that on October 7, 2026, Barclays initiated coverage of Insulet (NASDAQGS:PODD) (LSE:0ADR) with a Equal-Weight recommendation. This initiation follows a prior action on May 8, 2026, when the firm maintained its Underweight rating on the stock.Prior to this initiati
- Zacks · Sep 25, 8:45 AM EDTWhy Insulet (PODD) is a Top Growth Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- MarketBeat · Sep 25, 4:02 AM EDTInsulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum3 Medical Technology Stocks Outperforming in 2025Insulet (NASDAQ:PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing e
- Zacks · Sep 8, 9:24 AM EDTIs it Prudent to Retain Insulet Stock in Your Portfolio for Now?PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
- Zacks · Sep 7, 9:40 AM EDTInsulet (PODD) is a Top-Ranked Value Stock: Should You Buy?The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- Zacks · Sep 4, 11:30 AM EDTWhy Is Insulet (PODD) Up 8.1% Since Last Earnings Report?Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Aug 25, 9:33 AM EDTCan PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.
- The Motley Fool · Aug 24, 9:33 AM EDTInsulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?The executive acquired 1,100 shares at a weighted average price of $147.47 per share, representing a total transaction value of approximately $162,200.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Insulet Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.